An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer (original) (raw)
Related papers
Faraday discussions, 2015
Monitoring Prostate Cancer (PCa) biomarkers is an efficient way to diagnosis this disease early, since it improves the therapeutic success rate and suppresses PCa patient mortality: for this reason a powerful analytical technique such as electrochemiluminescence (ECL) is already used for this application, but its widespread usability is still hampered by the high cost of commercial ECL equipment. We describe an innovative approach for the selective and sensitive detection of the PCa biomarker sarcosine, obtained by a synergistic ECL-supramolecular approach, in which the free base form of sarcosine acts as co-reagent in a Ru(bpy)3(2+)-ECL process. We used magnetic micro-beads decorated with a supramolecular tetraphosphonate cavitand () for the selective capture of sarcosine hydrochloride in a complex matrix like urine. Sarcosine determination was then obtained with ECL measurements thanks to the complexation properties of , with a protocol involving simple pH changes - to drive the c...
A Rapid Method for the Detection of Sarcosine Using SPIONs/Au/CS/SOX/NPs for Prostate Cancer Sensing
International Journal of Molecular Sciences, 2018
Background: Sarcosine is an amino acid that is formed by methylation of glycine and is present in trace amounts in the body. Increased sarcosine concentrations in blood plasma and urine are manifested in sarcosinemia and in some other diseases such as prostate cancer. For this purpose, sarcosine detection using the nanomedicine approach was proposed. In this study, we have prepared superparamagnetic iron oxide nanoparticles (SPIONs) with different modified surface area. Nanoparticles (NPs) were modified by chitosan (CS), and sarcosine oxidase (SOX). SPIONs without any modification were taken as controls. Methods and Results: The obtained NPs were characterized by physicochemical methods. The size of the NPs determined by the dynamic light scattering method was as follows: SPIONs/Au/NPs (100–300 nm), SPIONs/Au/CS/NPs (300–700 nm), and SPIONs/Au/CS/SOX/NPs (600–1500 nm). The amount of CS deposited on the NP surface was found to be 48 mg/mL for SPIONs/Au/CS/NPs and 39 mg/mL for SPIONs/...
The Journal of Medical Research
Prostate cancer is a type of malignancy that is defined by abnormal development of cells in the prostate tissue. Prostate cancer needs early intervention since its incidence and prevalence is high across the world leading to high morbidity and mortality. Prostatic specific antigen test which is the commonly used screening test in Kenya and across the world is nonspecific, expensive and inaccessible to many people in rural setting who are in need. The definitive histological test is invasive and requires specialized facilities and personnel. This study sought to investigate sarcosine in urine as a predictor of prostate cancer to supplement prostatic specific antigen test in the diagnosis of prostate carcinoma. Cross sectional study design was employed in this study for all suspected prostate cancer identified according to clinical assessment during the study period. Midstream urine samples of about 30mls was collected in plastic tubes, centrifuged and supernatant collected and analyz...
Enzyme and microbial technology, 2018
An amperometric sarcosine biosensor was fabricated based on covalent immobilization of sarcosine oxidase (SarOx) onto the nanocomposite of carboxylated multi-walled carbon nanotubes (cMWCNT)/chitosan (CHIT) and copper nanoparticles (CuNPs), electrodeposited on gold (Au) electrode. The SarOx/CHIT/CuNPs/c-MWCNT/Au electrode was characterized by scanning electron microscopy (SEM), electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV). The enzyme electrode exhibited optimum current within 2 s at a potential of 0.2 V against Ag/AgCl, pH 7.0 and 35 °C. A linear relationship was obtained between sarcosine concentration in the range, 0.1-100 μM and current (mA) under optimum conditions. The biosensor exhibited a high sensitivity of 277.5 μA/μM/cm, a low detection limit of 0.1 pM and excellent storage stability (180 days). The analytical recoveries of added sarcosine in sera at 0.5 μM and at 1.0 μM concentration were 95.5% and 97.30 respectively. The precision i.e. within ...
Sarcosine as a potential prostate cancer biomarker and therapeutic target
Cancer Biology & Therapy, 2010
sarcosine; prostate cancer; biomarker; PSA; metastasis Unlike many solid tumors which present as a single mass, prostate cancer is usually multifocal and more difficult to detect. 1 Additionally, prostate cancer symptoms do not typically present until the cancer has reached an advanced stage. 2 As a result, physicians have consistently relied on biomarkers as indicators of the presence and progression of cancer; an ideal biomarker would allow the physician to determine cancerous tissue from non-cancerous, and perhaps even metastatic cancer from localized.
EXCLI Journal, 2018
Shortly after sarcosine was delineated as a potential biomarker for prostate cancer in 2009, a variety of analytical methods for clinical application were developed. Moreover, higher uptake of glycine in the mitochondria also played a role in cancer proliferation. A major constraint in the accurate quantification of sarcosine was the interference of the two isomers, α-alanine and β-alanine, using chromatographic separation techniques. Accordingly, we aimed to develop an analytical method for determining sarcosine and its related metabolites (α- and β-alanine, glycine and creatinine) under the same conditions by gas chromatography-tandem mass spectrometry (GC-MS/MS). BSTFA + 1 % TMCS was used for silylation, and GC-MS/MS conditions were optimized for the target analytes. The unique transition ions of sarcosine, α- and β-alanine, glycine and creatinine set up in MRM acquisition were m/z 116 → 73, 190 → 147, 176 → 147, 176 → 147 and 100 → 73, respectively. This newly developed method w...
Sensors and Actuators B: Chemical, 2019
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.